World Federation of Hemophilia
-
Act soon! Early bird registration ends this week
There’s never been a better time to register for the World Federation of Hemophilia (WFH) 2020 World Congress, in Kuala Lumpur from June 14 to...
-
The WFH wishes you a happy new year
Wishing you a happy new year. Meilleurs voeux pour la nouvelle année. Deseamos un feliz año nuevo.
-
Action plan developed at the WFH 2019 Africa summit to implement the 2017 declaration
The World Federation of Hemophilia (WFH) held its 3rd Africa Summit 2019 from September 3 to 4 in Johannesburg, South Africa, that brought together key...
-
A WFH Advisory on Particulate Matter in Emicizumab (HEMLIBRA) and Other Biologic Agents
Since the development of intravenous therapies, the presence of particulate matter in injectable drugs has been a concern for clinicians. While some particles can come...
-
WFH Board of Directors nominations opening soon
Members of the World Federation of Hemophilia (WFH) Board of Directors play a key role in setting the strategic direction of the WFH and ensuring...
-
Passionate hematologist and WFH volunteer passes away
On August 12, 2019, Shelby Lee Dietrich—a passionate hematologist and WFH volunteer—passed away at the age of 95. Her death is marked by the WFH,...
-
WFH welcomes Bayer to Humanitarian Aid Program
The WFH Humanitarian Aid Program aims to improve the lack of access to care and treatment for people with inherited bleeding disorders in developing countries,...
-
Now available: WFH Humanitarian Aid Program Impact Report 2018
A new report—called the “WFH Humanitarian Aid Program: Impact Report 2018”—has just been released. The document shows the impact that the WFH Humanitarian Aid Program...
-
Recommendation on the use of Cryoprecipitate
The Medical Advisory Board of the WFH has published recommendation on the use of Cryoprecipitate for Treatment of Congenital Bleeding Disorders, on 26 April 2019. The recommendations are as follows:...
-
Novo Nordisk announces FDA approves the Biologics License Application for ESPEROCT®
Novo Nordisk announces that the US Food and Drug Administration (FDA) has approved the Biologics License Application for turoctocog alfa pegol, N8-GP, (ESPEROCT)®, a recombinant extended half-life...
